On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a favorable opinion analyzing a pharmaceutical manufacturer’s ...
On this Ropes & Gray podcast, health care partner Michael Lampert and counsel Sam Perrone, and litigation & enforcement partner Andrew O’Connor, rejoin to discuss patient assistance programs, recent ...
Gemtesa’s manufacturer (Urovant Sciences) provides the Gemtesa Simple Savings Program. This is a financial assistance plan aimed at making Gemtesa (vibegron) — a treatment for overactive bladder in ...
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer Eligible patients were diagnosed with cancer and ...
This study increases our understanding of the operations and impact of PAPs from the perspective of safety-net clinics trying to help their indigent patients. Clinic staff reported widespread ...
Often referred to as AFPs, alternative funding programs are a third-party entity that works hand-in-hand with self-funded ...
BOSTON (Reuters) - The U.S. Internal Revenue Service is probing whether a patient-assistance charity wrongly gave a benefit to its pharmaceutical company donors by returning most of the money they ...
In the rapidly evolving landscape of healthcare, Pharma Patient Assistance Programs (PAP) have been a lifeline for many patients seeking access to essential medications. These programs aim to help ...
Yes, people with Medicare Part D who use Restasis may be eligible for a patient assistance program called myAbbVie Assist. This article discusses whether Medicare covers Restasis, Medicare ...
Ten case studies were conducted between December 2001 and March 2002 to identify critical issues to be explored more widely in a multistate telephone survey. The case-study sites were selected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results